Medical Foods For Inborn Errors Of Metabolism Market Scope And Analysis

Report Code : TIPRE00011389
Category : Life Sciences

No. of Pages : 150

Buy Now

Medical Foods for Inborn Errors of Metabolism Market Scope 2031

Buy Now

Medical Foods for Inborn Errors of Metabolism Market Report Scope

Report Attribute	Details
Market size in 2021	US$ 2.98 Billion
Market Size by 2031	US$ 9.76 Billion
Global CAGR (2023 - 2031)	13.4%
Historical Data	2021-2023
Forecast period	2023-2031
Segments Covered	By Product Amino Acid Glytactin with GMP Amino Acid-Modified Infant Formula with Iron Low-Calcium/Vitamin D-Free Infant Formula with Iron Low Protein Food By Age group Infants Weaning Adolescent Adults By Disease Phenylketonuria Maple Syrup Urine Disease Homocystinuria Urea Cycle Disorders Methylmalonic Acidemia Organic Acidurias Propionic Acidemia Isovaleric Acidemia Disorders of Leucine Metabolism Glutaric Acidemia Type I Renal Disease Tyrosinemia Types I and II By Forms Powder Liquids Gels
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	NA

Medical Foods for Inborn Errors of Metabolism Market News and Recent Developments

The medical foods for inborn errors of metabolism market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for medical foods for inborn errors of metabolism:

In October 2022, Galen launched TYR EASY Tablets, which is the first solid-dose protein substitute option for tyrosinaemia, in the UK market. The tablets are specifically designed to support dietary management for patients over the age of 8 with tyrosinaemia (TYR), providing them with more options for protein substitutes that best match their daily needs. (Source: Galen, Press Release, 2022)
In December 2021, SFI Health announced the launch of two new medical foods in the US: EQUAZEN PRO and Ther-Biotic PRO IBS Relief. Both medical foods have been made from clinically-proven ingredients and have undergone extensive testing in clinical studies to assess their safety and effectiveness. EQUAZEN® PRO helps rebalance omega fatty acid levels, while supporting healthy fatty acid metabolism. (Source: SFI Health, Press Release/Company Website/Newsletter, 2021)

Medical Foods for Inborn Errors of Metabolism Market Report Coverage and Deliverables

The “Medical Foods for Inborn Errors of Metabolism Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles